GlaxoSmithKline plc to Issue Dividend of GBX 19 (LON:GSK)

GlaxoSmithKline plc (LON:GSK) declared a dividend on Wednesday, July 29th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, August 13th will be given a dividend of GBX 19 ($0.23) per share on Thursday, October 8th. This represents a yield of 1.22%. The ex-dividend date of this dividend is Thursday, August 13th. The official announcement can be seen at this link.

Shares of GSK stock traded down GBX 50.80 ($0.63) during trading hours on Thursday, hitting GBX 1,553.80 ($19.12). The company’s stock had a trading volume of 8,367,957 shares, compared to its average volume of 9,120,000. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 159.26. The business has a fifty day moving average of GBX 1,626.70 and a 200-day moving average of GBX 1,638.38. GlaxoSmithKline has a twelve month low of GBX 16.27 ($0.20) and a twelve month high of GBX 1,857 ($22.85). The stock has a market cap of $77.96 billion and a price-to-earnings ratio of 14.52.

GlaxoSmithKline (LON:GSK) last posted its earnings results on Wednesday, April 29th. The company reported GBX 37.70 ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of GBX 31.10 ($0.38) by GBX 6.60 ($0.08). On average, equities analysts expect that GlaxoSmithKline will post 11385.0001492 EPS for the current fiscal year.

Several analysts have recently issued reports on GSK shares. Oddo Bhf restated a “neutral” rating and issued a GBX 1,840 ($22.64) price objective on shares of GlaxoSmithKline in a research report on Monday, June 22nd. Barclays reiterated an “underweight” rating on shares of GlaxoSmithKline in a report on Wednesday. Goldman Sachs Group set a GBX 2,060 ($25.35) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Wednesday, July 15th. Credit Suisse Group set a GBX 1,700 ($20.92) target price on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Thursday. Finally, UBS Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Monday. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,840.47 ($22.65).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Story: Different Options Trading Strategies

Dividend History for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.